Extracellular high-mobility group box 1 protein (HMGB1) as a mediator of persistent pain

Molecular Medicine

Volumn 20, Issue JULY/DECEMBER 2014, 2014, Pages 569-578

  Agalave, Nilesh M ^a   Svensson, Camilla I ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; HMGB1 PROTEIN, HUMAN;

ARTICLE; CHRONIC PAIN; DRUG TARGETING; EXPERIMENTAL PAIN; EXTRACELLULAR SPACE; HUMAN; MOLECULAR PATHOLOGY; NERVE INJURY; NERVOUS SYSTEM INFLAMMATION; NOCICEPTION; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM;

ANIMALS; CHRONIC PAIN; HMGB1 PROTEIN; HUMANS;

EID: 84922354536     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2014.00176     Document Type: Article

References (100)

1. Ueda T, Yoshida M. (2010) HMGB proteins and transcriptional regulation. Biochim. Biophys. Acta. 1799:114-8.
2. Andersson U, Tracey KJ. (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29:139-62.
3. Harris HE, Andersson U, Pisetsky DS. (2012) HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat. Rev. Rheumatol. 8:195-202.
4. Park JS, et al. (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279:7370-7.
5. van Beijnum JR, Buurman WA, Griffioen AW. (2008) Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 11:91-9.
6. Wang H, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248-51.
7. Maeda T, Ozaki M, Kobayashi Y, Kiguchi N, Kishioka S. (2013) HMGB1 as a potential therapeutic target for neuropathic pain. J. Pharmacol. Sci. 123:301-5.
8. Woolf CJ, Salter MW. (2000) Neuronal plasticity: increasing the gain in pain. Science. 288:1765-9.
9. Zeilhofer HU. (2005) Synaptic modulation in pain pathways. Rev. Physiol. Biochem. Pharmacol. 154:73-100.
10. Xu Q, Yaksh TL. (2011) A brief comparison of the pathophysiology of inflammatory versus neuropathic pain. Curr. Opin. Anaesthesiol. 24:400-7.
11. Costigan M, Scholz J, Woolf CJ. (2009) Neuropathic pain: a maladaptive response of the nervous system to damage. Annu. Rev. Neurosci. 32:1-32.
12. Gangadharan V, Kuner R. (2013) Pain hypersensitivity mechanisms at a glance. Dis. Model Mech. 6:889-95.
13. McMahon SB, Malcangio M. (2009) Current challenges in glia-pain biology. Neuron. 64:46-54.
14. Basbaum AI, Bautista DM, Scherrer G, Julius D. (2009) Cellular and molecular mechanisms of pain. Cell. 139:267-84.
15. Woolf CJ. (2010) What is this thing called pain? J. Clin. Invest. 120:3742-4.
16. Latremoliere A, Woolf CJ. (2009) Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J. Pain. 10:895-926.
17. Dublin P, Hanani M. (2007) Satellite glial cells in sensory ganglia: their possible contribution to inflammatory pain. Brain Behav. Immun. 21:592-8.
18. Zhang H, et al. (2009) Altered functional properties of satellite glial cells in compressed spinal ganglia. Glia. 57:1588-99.
19. Takeda M, et al. (2007) Enhanced excitability of nociceptive trigeminal ganglion neurons by satellite glial cytokine following peripheral inflammation. Pain. 129:155-66.
20. Svensson CI, Brodin E. (2010) Spinal astrocytes in pain processing: non-neuronal cells as therapeutic targets. Mol. Interv. 10:25-38.
21. Ji RR, Berta T, Nedergaard M. (2013) Glia and pain: is chronic pain a gliopathy? Pain. 154 Suppl 1: S10-28.
22. Grace PM, Hutchinson MR, Maier SF, Watkins LR. (2014) Pathological pain and the neuroimmune interface. Nat. Rev. Immunol. 14:217-31.
23. Tsung A, et al. (2007) HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J. Exp. Med. 204:2913-23.
24. Scaffidi P, Misteli T, Bianchi ME. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191-5.
25. Gardella S, et al. (2002) The nuclear protein HMGB1 is secreted by monocytes via a nonclassical, vesicle-mediated secretory pathway. EMBO Rep. 3:995-1001.
26. Kang R, et al. (2014) HMGB1 in health and disease. Mol. Aspects Med. 40C:1-116.
27. Jiang W, Pisetsky DS. (2006) The role of IFN-alpha and nitric oxide in the release of HMGB1 by RAW 264.7 cells stimulated with polyinosinic-polycytidylic acid or lipopolysaccharide. J. Immunol. 177:3337-43.
28. Lu B, et al. (2014) JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc. Natl. Acad. Sci. U. S. A. 111:3068-73.
29. Rendon-Mitchell B, et al. (2003) IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J. Immunol. 170:3890-7.
30. Zhou JR, et al. (2013) Neuropeptide Y induces secretion of high-mobility group box 1 protein in mouse macrophage via PKC/ERK dependent pathway. J. Neuroimmunol. 260:55-9.
31. Bonaldi T, et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22:5551-60.
32. Ito I, Fukazawa J, Yoshida M. (2007) Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J. Biol. Chem. 282:16336-44.
33. Zhang X, et al. (2008) Calcium/calmodulin-dependent protein kinase (CaMK) IV mediates nucleocytoplasmic shuttling and release of HMGB1 during lipopolysaccharide stimulation of macrophages. J. Immunol. 181:5015-23.
34. Ma L, Kim SJ, Oh KI. (2012) Calcium/calmodulin-dependent protein kinase is involved in the release of high mobility group box 1 via the interferonbeta signaling pathway. Immune Netw. 12:148-54.
35. Oh YJ, et al. (2009) HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J. Immunol. 182:5800-9.
36. Lu B, et al. (2012) Novel role of PKR in inflamma-some activation and HMGB1 release. Nature. 488:670-4.
37. Feldman P, Due MR, Ripsch MS, Khanna R, White FA. (2012) The persistent release of HMGB1 contributes to tactile hyperalgesia in a rodent model of neuropathic pain. J. Neuroinflam-mation. 9:180.
38. Allette YM, et al. (2014) Identification of a functional interaction of HMGB1 with receptor for advanced glycation end-products in a model of neuropathic pain. Brain Behav. Immun. 42:169-77.
39. Pedrazzi M, et al. (2012) Potentiation of NMDA receptor-dependent cell responses by extracellular high mobility group box 1 protein. PLoS One. 7:e44518.
40. Balosso S, Liu J, Bianchi ME, Vezzani A. (2014) Disulfide-containing high mobility group box-1 promotes N-methyl-D-aspartate receptor function and excitotoxicity by activating Toll-like receptor 4-dependent signaling in hippocampal neurons. Antioxid. Redox. Signal. 21:1726-40.
41. Chiavegato A, Zurolo E, Losi G, Aronica E, Carmignoto G. (2014) The inflammatory molecules IL-1β and HMGB1 can rapidly enhance focal seizure generation in a brain slice model of temporal lobe epilepsy. Front. Cell. Neurosci. 8:155.
42. Hori O, et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin: mediation of neurite out-growth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270:25752-61.
43. Ivanov S, et al. (2007) A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood. 110:1970-81.
44. Chen GY, Tang J, Zheng P, Liu Y. (2009) CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 323:1722-5.
45. Orlova VV, et al. (2007) A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 26:1129-39.
46. Sha Y, Zmijewski J, Xu Z, Abraham E. (2008) HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J. Immunol. 180:2531-7.
47. Campana L, Bosurgi L, Bianchi ME, Manfredi AA, Rovere-Querini P. (2009) Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J. Leukoc. Biol. 86:609-15.
48. Hreggvidsdottir HS, et al. (2012) High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol. Med. 18:224-30.
49. Venereau E, et al. (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209:1519-28.
50. Yang H, et al. (2012) Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol. Med. 18:250-9.
51. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. (2002) Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 62:4805-11.
52. McMahon SB, Cafferty WB, Marchand F. (2005) Immune and glial cell factors as pain mediators and modulators. Exp. Neurol. 192:444-62.
53. Wadachi R, Hargreaves KM. (2006) Trigeminal nociceptors express TLR-4 and CD14: a mechanism for pain due to infection. J. Dent. Res. 85:49-53.
54. Li Y, et al. (2014) Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy. J. Pain. 15:712-25.
55. Due MR, et al. (2012) Neuroexcitatory effects of morphine-3-glucuronide are dependent on Toll-like receptor 4 signaling. J. Neuroinflammation. 9:200.
56. Shibasaki M, et al. (2010) Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury. Pain. 149:514-21.
57. Nicotra L, Loram LC, Watkins LR, Hutchinson MR. (2012) Toll-like receptors in chronic pain. Exp. Neurol. 234:316-29.
58. Chacur M, et al. (2001) A new model of sciatic inflammatory neuritis (SIN): induction of unilateral and bilateral mechanical allodynia following acute unilateral peri-sciatic immune activation in rats. Pain. 94:231-44.
59. Tanaka J, et al. (2013) Recombinant human soluble thrombomodulin prevents peripheral HMGB1-dependent hyperalgesia in rats. Br. J. Pharmacol. 170:1233-41.
60. Milligan ED, et al. (2003) Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J. Neurosci. 23:1026-40.
61. Tanaka J, et al. (2014) Bladder pain relief by HMGB1 neutralization and soluble thrombomodulin in mice with cyclophosphamide-induced cystitis. Neuropharmacology. 79:112-8.
62. Kokkola R, et al. (2002) High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum. 46:2598-603.
63. Pullerits R, et al. (2003) High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum. 48:1693-700.
64. O’Connor KA, et al. (2003) Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: central nervous system effects. Cytokine. 24:254-65.
65. Agalave NM, et al. (2014) Spinal HMGB1 induces TLR4-mediated long-lasting hypersensitivity and glial activation and regulates pain-like behavior in experimental arthritis. Pain. 155:1802-13.
66. Hoppe G, Talcott KE, Bhattacharya SK, Crabb JW, Sears JE. (2006) Molecular basis for the redox control of nuclear transport of the structural chro-matin protein Hmgb1. Exp. Cell. Res. 312:3526-38.
67. Calogero S, et al. (1999) The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet. 22:276-80.
68. Kang R, et al. (2014) Intracellular Hmgb1 inhibits inflammatory nucleosome release and limits acute pancreatitis in mice. Gastroenterology. 146:1097-107.
69. Yanai H, et al. (2013) Conditional ablation of HMGB1 in mice reveals its protective function against endotoxemia and bacterial infection. Proc. Natl. Acad. Sci. U. S. A. 110:20699-704.
70. Kokkola R, et al. (2003) Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 48:2052-8.
71. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. (2002) HMGB1 as a DNA-binding cytokine. J. Leukoc. Biol. 72:1084-91.
72. Yang H, et al. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U. S. A. 101:296-301.
73. Mollica L, et al. (2007) Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem. Biol. 14:431-41.
74. Abeyama K, et al. (2005) The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest. 115:1267-74.
75. Nakamura Y, et al. (2013) Neuropathic pain in rats with a partial sciatic nerve ligation is alleviated by intravenous injection of monoclonal antibody to high mobility group box-1. PLoS One. 8:e73640.
76. Otoshi K, Kikuchi S, Kato K, Sekiguchi M, Konno S. (2011) Anti-HMGB1 neutralization antibody improves pain-related behavior induced by application of autologous nucleus pulposus onto nerve roots in rats. Spine (Phila Pa 1976).36:E692-8.
77. Wahamaa H, et al. (2011) High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Res. Ther. 13:R136.
78. Hreggvidsdottir HS, et al. (2009) The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J. Leukoc. Biol. 86:655-62.
79. Tong W, et al. (2010) Spinal high-mobility group box 1 contributes to mechanical allodynia in a rat model of bone cancer pain. Biochem. Biophys. Res. Commun. 395:572-6.
80. Ren PC, et al. (2012) High-mobility group box 1 contributes to mechanical allodynia and spinal astrocytic activation in a mouse model of type 2 diabetes. Brain Res. Bull. 88:332-7.
81. Bas DB, et al. (2012) Collagen antibody-induced arthritis evokes persistent pain with spinal glial involvement and transient prostaglandin dependency. Arthritis Rheum. 64:3886-96.
82. Su J, et al. (2015) Phenotypic changes in dorsal root ganglion and spinal cord in the collagen antibody-induced arthritis mouse model. J. Comp. Neurol. 2015, Jan 29 [Epub ahead of print].
83. Kim ID, Lee JK. (2013) HMGB1-binding heptamer confers anti-inflammatory effects in primary microglia culture. Exp. Neurobiol. 22:301-7.
84. Kim SW, et al. (2012) Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion. Neurobiol. Dis. 46:147-56.
85. Shin JH, Lee HK, Lee HB, Jin Y, Lee JK. (2014) Ethyl pyruvate inhibits HMGB1 phosphorylation and secretion in activated microglia and in the postischemic brain. Neurosci. Lett. 558:159-63.
86. Zurolo E, et al. (2011) Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. Brain. 134:1015-32.
87. Kim JB, et al. (2006) HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J. Neurosci. 26:6413-21.
88. Laird MD, et al. (2014) High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4. Glia. 62:26-38.
89. Pedrazzi M, et al. (2007) Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling. J. Immunol. 179:8525-32.
90. Qiu J, et al. (2010) High-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia. Stroke. 41:2077-82.
91. Bonanno G, et al. (2007) The high-mobility group box 1 cytokine induces transporter-mediated release of glutamate from glial subcellular particles (gliosomes) prepared from in situ-matured astrocytes. Int. Rev. Neurobiol. 82:73-93.
92. Antoine DJ, et al. (2009) High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol. Sci. 112:521-31.
93. Zetterstrom CK, et al. (2008) Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. J. Leukoc. Biol. 83:31-8.
94. Tsai CY, et al. (2012) Size-dependent attenuation of TLR9 signaling by gold nanoparticles in macrophages. J. Immunol. 188:68-76.
95. Ostberg T, et al. (2008) Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. Arthritis Res. Ther. 10:R1.
96. Ling B, Authier N, Balayssac D, Eschalier A, Coudore F. (2007) Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain. 128:225-34.
97. Ling B, et al. (2007) Behavioral and immunohis-tological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat. Toxicology. 234:176-84.
98. Melemedjian OK, et al. (2011) Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol. Pain. 7:70.
99. He Z, Guo Q, Xiao M, He C, Zou W. (2013) Intrathecal lentivirus-mediated transfer of inter-leukin-10 attenuates chronic constriction injuryinduced neuropathic pain through modulation of spinal high-mobility group box 1 in rats. Pain Physician. 16:E615-25.
100. Kuang X, et al. (2012) Effects of intrathecal epigallocatechin gallate, an inhibitor of Toll-like receptor 4, on chronic neuropathic pain in rats. Eur. J. Pharmacol. 676:51-6.